The proposed legislation, which prevents U.S. federal funds from supporting certain Chinese contract manufacturers, was omitted from a defense bill leaving its fate in limbo.
The regulator’s draft strategy offers a potential roadmap to modernize production and enhance efficiency. However, ARM, BIO and PhRMA want to see changes to the document.
The companies say they will develop a platform capable of supporting rapid dry powder inhaler development in less than half the time typically required.
